Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 7 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell CarcinomaCompletedNCT04137627Phase 3Results posted
• Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT04128696Phase 3Results posted
• A Study of LY3435151 in Participants With Solid TumorsTerminatedNCT04099277Phase 1Results posted
• Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCCCompletedNCT04098458Not applicableResults posted
• Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsTerminatedNCT04052204Phase 1/2Results posted
• Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHNTerminatedNCT04034225Phase 1/2Results posted
• A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsTerminatedNCT04032704Phase 2Results posted
• Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerActive, not recruitingNCT04030455Phase 2Results posted
• Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCCCompletedNCT04030130Not applicableResults posted
• An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.CompletedNCT03998696Phase 2Results posted
• Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck CancerCompletedNCT03993353Phase 2Results posted
• INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation TherapyCompletedNCT03953976Phase 2Results posted
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal CancerActive, not recruitingNCT03952585Phase 2/3Results posted
• De-Escalation Therapy for Human Papillomavirus Negative DiseaseCompletedNCT03944915Phase 2Results posted
• SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03894618Phase 1Results posted
• Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNCompletedNCT03878979Phase 2Results posted
• Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckTerminatedNCT03854032Phase 2Results posted
• Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck CancerCompletedNCT03829722Phase 2Results posted
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesTerminatedNCT03829501Phase 1/2Results posted
• Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and EpacadostatTerminatedNCT03823131Phase 2Results posted
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results posted
• IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaCompletedNCT03795610Phase 2Results posted
• Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell CarcinomaCompletedNCT03768856Not applicableResults posted
• Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsTerminatedNCT03740100Phase 2Results posted
• A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of CancerCompletedNCT03735680Phase 2Results posted
• Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck CancerCompletedNCT03733210Phase 1Results posted
• MGC018 With or Without MGA012 in Advanced Solid TumorsTerminatedNCT03729596Phase 1/2Results posted
• Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyCompletedNCT03719690Phase 2Results posted
• Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx CancerCompletedNCT03715946Phase 2Results posted
• Arginase-1 Peptide Vaccine in Patients With Metastatic Solid TumorsCompletedNCT03689192Phase 1Results posted
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
• A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT03665285Phase 1/2Results posted
• Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyTerminatedNCT03655444Phase 1/2Results posted
• Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03650764Phase 1/2Results posted
• Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCTerminatedNCT03646461Phase 2Results posted
• Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCCompletedNCT03625323Phase 2Results posted
• A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer PatientsCompletedNCT03602911Phase 2Results posted
• Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal CancerTerminatedNCT03601507Phase 2Results posted
• Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCCCompletedNCT03552965Not applicableResults posted
• Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.TerminatedNCT03525392Phase 1Results posted
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT03522584Phase 1/2Results posted
• Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerCompletedNCT03521570Phase 2Results posted
• Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell CarcinomaCompletedNCT03502148Phase 1/2Results posted
• UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeActive, not recruitingNCT03474497Phase 1/2Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior ImmunotherapyTerminatedNCT03463161Phase 2Results posted
• A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminatedNCT03452137Phase 3Results posted
• A Study of E7130 in Participants With Solid TumorsTerminatedNCT03444701Phase 1Results posted
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2Results posted
• Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell CarcinomaCompletedNCT03422536Phase 2Results posted
• Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck CancerCompletedNCT03405142Phase 2Results posted
• Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03389477Phase 2Results posted
• Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedNCT03386357Phase 2Results posted
• Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03370276Phase 1/2Results posted
• Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)CompletedNCT03358472Phase 3Results posted
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerCompletedNCT03349710Phase 3Results posted
• Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SurgeryCompletedNCT03342911Phase 2Results posted
• Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNActive, not recruitingNCT03341936Phase 2Results posted
• Priming Immunotherapy in Advanced Disease With RadiationCompletedNCT03313804Phase 2Results posted
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results posted
• A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT03254927Phase 2Results posted
• Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
• Phase Ib of L-NMMA and PembrolizumabCompletedNCT03236935Phase 1Results posted
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
• Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03194373Phase 2Results posted
• Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03174275Phase 2Results posted
• Ruxolitinib in Operable Head and Neck CancerTerminatedNCT03153982Phase 2Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• AVID100 in Advanced Epithelial CarcinomasTerminatedNCT03094169Phase 1/2Results posted
• Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity CancerTerminatedNCT03090412Phase 2Results posted
• Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckCompletedNCT03083873Phase 2Results posted
• Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03082534Phase 2Results posted
• The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and NeckCompletedNCT03057613Phase 2Results posted
• Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral CancerTerminatedNCT03053960Results posted
• Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475CompletedNCT03049618Phase 2Results posted
• Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)CompletedNCT03040999Phase 3Results posted
• Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck CancerCompletedNCT03032250Not applicableResults posted
• Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity CancerCompletedNCT03021993Phase 2Results posted
• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)TerminatedNCT02952586Phase 3Results posted
• Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell CarcinomaCompletedNCT02949700Phase 1/2Results posted
• ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive TreatmentTerminatedNCT02917629Phase 2Results posted
• Pembrolizumab in HNSCC With Residual Disease After RadiationTerminatedNCT02892201Phase 2Results posted
• A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay StudyCompletedNCT02841748Phase 2Results posted
• Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerTerminatedNCT02827838Early Phase 1Results posted
• Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02823574Phase 2Results posted
• PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02819752Phase 1Results posted
• Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck CancerCompletedNCT02777385Phase 2Results posted
• Expansion Trial for Axitinib In Head And Neck CancerCompletedNCT02762513Phase 2Results posted
• A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell CarcinomaCompletedNCT02759575Phase 1/2Results posted
• Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02741570Phase 3Results posted
• BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck CancerTerminatedNCT02706691Phase 2Results posted
• Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT02684253Phase 2Results posted
• A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results posted
• Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)CompletedNCT02626000Phase 1Results posted
• Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)CompletedNCT02573493Phase 2Results posted
• Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT02567422Phase 1Results posted
• Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck CancerCompletedNCT02551159Phase 3Results posted
• Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by SurgeryCompletedNCT02538510Phase 1/2Results posted
• Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02524275Phase 2Results posted
• A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT02521870Phase 1/2Results posted

← Squamous Cell Carcinoma of Head and Neck overview